Type I Error

A Type I error, also called a false positive, occurs when a statistical test incorrectly rejects a true null hypothesis, concluding that an effect or difference exists when it does not. The probability of committing a Type I error is denoted by alpha and is set by the researcher before conducting the analysis, typically at 0.05 (5%). This means that if the null hypothesis is true, there is a 5% chance of obtaining a test result that leads to its rejection. Type I error control is a fundamental principle of frequentist hypothesis testing and guides the design and interpretation of statistical analyses across many scientific disciplines.

Type I errors lead to false claims of effectiveness, false associations, and false discoveries. In clinical medicine, a Type I error could lead to the adoption of a treatment that is no better than placebo, exposing patients to unnecessary risks and costs. In drug development, it could trigger expensive large scale trials based on a false signal from an earlier phase study. In basic science, it contributes to the accumulation of non replicable findings that undermine scientific credibility. The alpha level represents the researcher's tolerance for this type of mistake, and the choice of alpha level balances the desire to detect true effects against the need to avoid false claims. More stringent alpha levels (such as 0.01 or 0.005) reduce Type I errors but increase the risk of missing true effects (Type II errors), requiring the researcher to consider both types of error in study planning.

In frequentist hypothesis testing, the researcher sets the alpha level before the analysis, and the null hypothesis is rejected only if the p value falls below this threshold. The alpha level directly controls the probability of a Type I error for a single test. However, when multiple hypothesis tests are conducted simultaneously, the probability that at least one test produces a Type I error (the familywise error rate) increases rapidly. For example, conducting 20 independent tests each at alpha = 0.05 yields a familywise error probability of approximately 64%. To control the familywise error rate, researchers apply multiple comparison corrections such as the Bonferroni adjustment (dividing alpha by the number of tests) or the Holm procedure (a step down method with more power than Bonferroni); the Benjamini Hochberg procedure instead controls the false discovery rate, the expected proportion of false positives among the significant results. In clinical trials, interim analyses create additional opportunities for Type I error, managed through group sequential stopping boundaries, such as O'Brien Fleming or Pocock boundaries, or alpha spending functions, which allocate portions of the overall alpha across planned interim looks at the data.

Consider Type I error whenever conducting or interpreting a hypothesis test. Set the alpha level at the design stage and report it in the methods section. Apply multiple comparison corrections when several tests could each support a claim, as when testing more than one hypothesis, analyzing multiple outcomes, or performing subgroup analyses. In confirmatory clinical trials, the alpha level and multiple testing strategy should be specified in the protocol and statistical analysis plan before unblinding. In exploratory research, where the goal is hypothesis generation rather than confirmation, more liberal alpha levels or false discovery rate control may be acceptable, but the exploratory nature of the analysis should be clearly stated.

A common mistake is conducting multiple statistical tests without adjusting for multiplicity, leading to an inflated Type I error rate. Another frequent error is interpreting a p value just below 0.05 as strong evidence against the null hypothesis when, by definition, 5% of tests of true null hypotheses will produce a p value below 0.05 by chance. Researchers sometimes confuse the alpha level with the probability that the null hypothesis is true given a significant result, which is a misinterpretation; the alpha level is the probability of a significant result given that the null hypothesis is true, not the reverse. Post hoc hypothesis testing, in which the hypothesis is formulated after seeing the data, also inflates the true Type I error rate beyond the nominal alpha level because the test is no longer independent of the data. Selective reporting of significant results from a larger set of analyses without disclosure is another form of undisclosed multiplicity that inflates apparent significance.

A pharmaceutical company conducts a phase III trial with one primary outcome (pain reduction) and four secondary outcomes (physical function, sleep quality, mood, and patient global assessment). The protocol specifies a significance level of 0.05 for the primary outcome and tests the secondary outcomes only if the primary outcome is significant, using the Holm procedure to control the familywise error rate across them. The primary outcome is significant (p = 0.008). Among the secondary outcomes, physical function (p = 0.003) and sleep quality (p = 0.012) are significant after the Holm adjustment, but mood (p = 0.047) and patient global assessment (p = 0.062) are not. Without the multiple testing correction, mood would have appeared significant; the correction guards against a possible Type I error so that only outcomes that meet the adjusted thresholds are declared significant.